The race for antiviral drugs to beat COVID - and the next pandemic.

@article{Dolgin2021TheRF,
  title={The race for antiviral drugs to beat COVID - and the next pandemic.},
  author={Elie S Dolgin},
  journal={Nature},
  year={2021},
  volume={592 7854},
  pages={
          340-343
        }
}
  • E. Dolgin
  • Published 1 April 2021
  • Medicine
  • Nature
An update of anti-viral treatment of COVID-19
TLDR
Monoclonal antibodies seem to be the most effective treatment for COVID-19 at the moment, and high-titer convalescent plasma also could be effective when administered during the early phase of the disease.
Untapping host-targeting cross-protective efficacy of anticoagulants against SARS-CoV-2
Broad spectrum antiviral nucleosides—Our best hope for the future
Doxycycline Inhibition of a Pseudotyped Virus Transduction Does Not Translate to Inhibition of SARS-CoV-2 Infectivity
TLDR
Doxycycline inhibited the transduction of the pseudotyped virus in Vero E6 and HEK-293 T cells stably expressing human receptor angiotensin-converting enzyme 2 but did not affect the entry and replication of SARS-CoV-2.
Doxycycline inhibition of a pseudotyped virus transduction does not translate to inhibition of SARS-CoV-2 infectivity
TLDR
Doxycycline inhibited the transduction of the pseudotyped virus in Vero E6 and HEK-293 T cells stably expressing human receptor angiotensin-converting enzyme 2 but did not affect the entry and replication of SARS-CoV-2.
Efficacy of repurposed antiviral drugs: Lessons from COVID-19
Enabling evidence to tackle everyday diseases to mitigate another pandemic
  • T. Lang
  • Medicine
    Gates Open Research
  • 2022
TLDR
The next emergent novel pathogen is likely to occur where the ability to undertake health research and collect life-saving data is lacking, thereby enabling undetected infection and unchecked transmission within a community.
Insights Into Drug Repurposing, as Well as Specificity and Compound Properties of Piperidine-Based SARS-CoV-2 PLpro Inhibitors
TLDR
This work reports an effort to identify PLpro inhibitors by screening the ReFRAME library of 11,804 compounds, showing that none inhibit PLpro with any reasonable activity or specificity, and arrives at compounds with improved and favorable solubility and stability characteristics that are tested for inhibiting viral replication.
Insights into the binding and covalent inhibition mechanism of PF-07321332 to SARS-CoV-2 Mpro
TLDR
It is found that the catalytic triad Cys145–His41–Asp187 of SARS-CoV-2 Mpro plays an important role in the activation of the PF-07321332 covalent inhibitor, which renders the deprotonation of Cys 145 and, thus, facilitates further reaction.
...
1
2
3
4
...

References

SHOWING 1-6 OF 6 REFERENCES
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
A ribonucleoside analog inhibits SARS-CoV-2 in human airway epithelial cell cultures and SARS-CoV and MERS-CoV in mice. Catastrophic consequences Broad-spectrum antivirals are desirable, particularly
Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19
TLDR
Preclinical experiments reveal 4 (PF-00835231) as a potent inhibitor of CoV-2 3CLpro with suitable pharmaceutical properties to warrant further development as an intravenous treatment for COVID-19.
Remdesivir for the Treatment of Covid-19 — Final Report
TLDR
The data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection.
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
TLDR
These remdesivir, hydroxychloroquine, lopinavir, and interferon regimens had little or no effect on hospitalized patients with Covid-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay.
Therapeutic treatment of Zika virus infection using a brain-penetrating antiviral peptide
TLDR
An amphiphatic peptide is now shown to penetrate the blood–brain barrier, reducing viral loads due to its activity against Zika and other mosquito-borne viruses.
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
TLDR
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses in vitro and in vivo and may prove effective against endemic MERS-CoV in the Middle East, circulating human CoV, and, possibly most importantly, emerging CoV of the future.